INKT Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
MiNK Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.00 |
52 Week High | US$3.34 |
52 Week Low | US$0.75 |
Beta | 0.033 |
1 Month Change | 14.81% |
3 Month Change | 11.11% |
1 Year Change | -48.45% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -91.67% |
Recent News & Updates
Recent updates
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05Shareholder Returns
INKT | US Biotechs | US Market | |
---|---|---|---|
7D | -3.8% | 0.07% | -0.2% |
1Y | -48.5% | 6.9% | 28.2% |
Return vs Industry: INKT underperformed the US Biotechs industry which returned 6.9% over the past year.
Return vs Market: INKT underperformed the US Market which returned 28.2% over the past year.
Price Volatility
INKT volatility | |
---|---|
INKT Average Weekly Movement | 16.6% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: INKT's share price has been volatile over the past 3 months.
Volatility Over Time: INKT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 31 | Jen Buell | minktherapeutics.com |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. Fundamentals Summary
INKT fundamental statistics | |
---|---|
Market cap | US$34.70m |
Earnings (TTM) | -US$20.59m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs INKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INKT income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$20.59m |
Earnings | -US$20.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.59 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -20.7% |
How did INKT perform over the long term?
See historical performance and comparison